Applied Dna Sciences Inc (BNBX)

Oct 6, 2025, 8:00 AM EDT - 3 days ago

Applied DNA Sciences to Begin Trading Under New Ticker ‘BNBX' Reflecting Digital Asset Treasury Strategy

Sep 29, 2025, 3:08 PM EDT - 10 days ago

Applied DNA Sciences Announces Private Placement of Up To $58 Million To Initiate BNB Treasury Strategy and BNB Native Yield Generation

Sep 23, 2025, 8:30 AM EDT - 16 days ago

Applied DNA Abstracts Selected for Poster Presentations Showcasing LineaDNA and LineaIVT Platforms at Upcoming mRNA and CAR T Industry Conferences

Aug 14, 2025, 4:10 PM EDT - 2 months ago

Applied DNA Reports Third Quarter Fiscal 2025 Financial Results

Jul 24, 2025, 9:00 AM EDT - 2 months ago

Applied DNA Announces New Follow-On LineaDNA Order from Global IVD Manufacturer for Use in Cancer Diagnostic Application

Jul 7, 2025, 9:00 AM EDT - 3 months ago

Applied DNA Regains Compliance with All Nasdaq Continued Listing Requirements

Jun 30, 2025, 9:00 AM EDT - 3 months ago

Applied DNA Sharpens Strategic Focus on Synthetic DNA Manufacturing for Biotherapeutics Applications, Consolidates Operations Behind LineaRx

Jun 17, 2025, 4:10 PM EDT - 4 months ago

Applied DNA Announces Retirement of Chairperson and CEO Dr. James A. Hayward

Jun 16, 2025, 9:00 AM EDT - 4 months ago

Applied DNA to Resume Quarterly Investor Call Cadence Beginning with FQ3'25 Financial Results Report in Mid-August

May 29, 2025, 8:00 AM EDT - 4 months ago

Applied DNA Announces 1-For-15 Reverse Stock Split Effective June 2, 2025

May 15, 2025, 4:05 PM EDT - 5 months ago

Applied DNA Reports Second Quarter Fiscal 2025 Financial Results

May 14, 2025, 11:30 AM EDT - 5 months ago

Applied DNA to Announce Second Quarter Fiscal 2025 Financial Results on May 15, Schedules Intra-Quarter Investor Update Call for June 3

Apr 21, 2025, 9:00 AM EDT - 6 months ago

Applied DNA's LineaRx Subsidiary Stands Ready to Support the Reshoring of Drug Development and Manufacturing with U.S.-Produced Synthetic DNA

Apr 8, 2025, 9:00 AM EDT - 6 months ago

Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement

Apr 1, 2025, 9:45 AM EDT - 6 months ago

Applied DNA Positions TR8 PGx Testing Service as Pre-Emptive Testing for Safety of Fluoropyrimidine-Based Cancer Therapeutics Following Publication of Food and Drug Administration Safety Announcement

Mar 26, 2025, 9:00 AM EDT - 7 months ago

Applied DNA Submits Validation Package to New York State Department of Health for H5 Bird Flu/Pan-Influenza A Laboratory-Developed Test

Mar 12, 2025, 8:00 AM EDT - 7 months ago

Applied DNA Announces 1-For-50 Reverse Stock Split Effective March 14, 2025

Feb 14, 2025, 2:10 PM EST - 8 months ago

Applied DNA Sciences, Inc. (APDN) Q1 2025 Earnings Call Transcript

Feb 13, 2025, 4:03 PM EST - 8 months ago

Applied DNA Reports First Quarter Fiscal 2025 Financial Results and Highlights Operational Progress

Feb 12, 2025, 12:00 PM EST - 8 months ago

Applied DNA to Report First Quarter Fiscal 2025 Financial Results After Market Close on Thursday, February 13, 2025

Feb 11, 2025, 8:30 AM EST - 8 months ago

Applied DNA Reminds Shareholders to Vote Ahead of Special Meeting on February 14

Jan 10, 2025, 9:00 AM EST - 9 months ago

Applied DNA Completes Buildout of GMP Facility for LineaDNA IVT Templates

Jan 8, 2025, 4:30 PM EST - 9 months ago

Applied DNA Reschedules Investor Update Call in Observance of the National Day of Mourning in Recognition of the Passing of Former President Jimmy Carter

Dec 18, 2024, 9:00 AM EST - 10 months ago

Applied DNA Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-Cell Therapy Produced from Linea DNA

Dec 17, 2024, 4:05 PM EST - 10 months ago

Applied DNA Announces Fourth Quarter and Fiscal Year 2024 Financial Results, Announces Strategic Restructuring to Prioritize the Manufacture of Critical Starting Materials for Genetic Medicines

Dec 16, 2024, 10:00 AM EST - 10 months ago

Applied DNA to Report Fourth Quarter and Fiscal Year 2024 Financial Results After Market Close on December 17, 2024; Sets Webcast and Conference Call for January 9, 2025, to Coincide with Update on GMP Manufacturing Facility Build-out

Oct 30, 2024, 7:15 AM EDT - 1 year ago

Applied DNA Announces Pricing of $6.5 Million Registered Direct Offering and Concurrent Private Placement

Oct 15, 2024, 10:30 AM EDT - 1 year ago

Applied DNA to Participate in the 2024 Maxim Healthcare Virtual Summit on Wednesday, October 16

Sep 17, 2024, 9:15 AM EDT - 1 year ago

Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 3rd Annual mRNA Process Development & Manufacturing Summit

Sep 17, 2024, 9:00 AM EDT - 1 year ago

Applied DNA Receives Linea DNA Follow-on Order from Global Manufacturer of IVDs for Cancer Diagnostic Application

Sep 11, 2024, 9:00 AM EDT - 1 year ago

Applied DNA Launches Mpox Clade I and Clade II Testing Service

Sep 4, 2024, 9:00 AM EDT - 1 year ago

Applied DNA Selected by LRQA for Isotopic Testing Pilot Project in Pakistan

Aug 23, 2024, 1:19 PM EDT - 1 year ago

Why Is Diagnostic Tests Provider Applied DNA Sciences Stock Trading Higher On Friday?

Aug 23, 2024, 9:00 AM EDT - 1 year ago

Applied DNA Submits Validation Package to New York State Department of Health to Expand Linea Mpox Virus 1.0 Assay to Mpox Clade I

Aug 19, 2024, 3:25 PM EDT - 1 year ago

Applied DNA To Submit Application to New York State Department of Health to Expand Intended Use of Linea Mpox Virus 1.0 Assay to Mpox Clade I

Aug 11, 2024, 12:29 PM EDT - 1 year ago

Applied DNA Sciences, Inc. (APDN) Q3 2024 Earnings Call Transcript

Aug 8, 2024, 4:10 PM EDT - 1 year ago

Applied DNA Announces Third Quarter Fiscal Year 2024 Financial Results

Aug 7, 2024, 8:00 AM EDT - 1 year ago

Applied DNA to Report Third Quarter Fiscal 2024 Financial Results on Thursday, August 8, 2024

Jul 29, 2024, 11:57 AM EDT - 1 year ago

CORRECTING AND REPLACING: Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 4th Annual mRNA-based Therapeutics Summit

Jul 29, 2024, 11:10 AM EDT - 1 year ago

Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 4th Presentation Annual mRNA-based Therapeutics Summit

Jul 25, 2024, 9:00 AM EDT - 1 year ago

Applied DNA Enters into Multi-Year Commercialization Agreement with Indus Group for Large-Scale Implementation of CertainT Cotton Traceability

Jul 18, 2024, 10:00 AM EDT - 1 year ago

U.S. Defense Logistics Agency Exercises 1-Year Option Period in Applied DNA Counterfeit Mitigation Contract

Jun 20, 2024, 9:15 AM EDT - 1 year ago

Applied DNA and Alphazyme Conclude Linea(TM) RNAP Manufacturing Scale-up Project, Deliver Substantial Improvement in Linea(TM) IVT Platform Economics

MRVI

Jun 18, 2024, 9:00 AM EDT - 1 year ago

Applied DNA Partners with GenXys Health Care Systems to Deploy Clinical Decision Support System for Pharmacogenetic (PGx) Testing

Jun 13, 2024, 9:00 AM EDT - 1 year ago

Applied DNA Receives Approval for TR8(TM) Pharmacogenomic (PGx) Testing Service from New York State Department of Health

Jun 10, 2024, 1:14 PM EDT - 1 year ago

Time to Play 5 Top-Ranked Stocks With Rising P/E?

AMC HCAT XGN YOU

Jun 5, 2024, 9:00 AM EDT - 1 year ago

Applied DNA Announces Notice of Allowance for U.S. Patent Covering Fundamental Aspect of its Linea(TM) IVT Platform

May 13, 2024, 8:55 AM EDT - 1 year ago

Institute of Hematology and Blood Transfusion (Prague) to Present on Successful Use of Applied DNA's Linea DNATM for the Non-Viral Manufacture of CAR T-Cell Therapy for Refractory AML

May 10, 2024, 4:05 PM EDT - 1 year ago

Applied DNA Announces Second Quarter Fiscal Year 2024 Financial Results

Apr 25, 2024, 9:00 AM EDT - 1 year ago

Applied DNA Awarded Contract by HDT Bio For Rapid Vaccine Development Program